President and Chief Executive Officer @ Omniome (September 2017 - January 2021)
Lifecycle Leader, Site Head and Chief Operations Officer - Ariosa @ Roche Molecular Solutions (January 2015 - January 2017)
President and Chief Operations Officer @ (January 2014 - January 2015)
Senior Vice President and General Manager, Dermatology @ Valeant Pharmaceuticals Intl (January 2009 - January 2013)
Vice President, Marketing @ (January 2006 - December 2008)
Director, Global Commercial Leader and Director, Marketing Excellence @ (January 2001 - January 2006)
Executive Director, Business Development @ (January 1997 - January 2001)
Senior Associate, Management Consultant @ (January 1993 - January 1997)
Specialty Sales Representative @ Eli Lilly and Company (January 1988 - January 1992)
Dave Mullarkey Education
Cornell University
B.S. (Applied Economics & Business Management - Dyson School of Management)
Northwestern University - Kellogg School of Management
M.B.A. (Marketing and Strategy)
Dave Mullarkey Skills
Biotechnology
Bottom Line Growth
Business Development
Business Planning
Change Management
Clinical Trials
Competitive Analysis
Cross-functional Team Leadership
Dermatology
EBITDA
Executive Management
Fundraising
Global Marketing
Growth Initiatives
Growth Strategies
Healthcare
Leadership
Licensing
Lifesciences
Management
Market Planning
Marketing
Marketing Strategy
Medical Devices
Mergers & Acquisitions
New Business Development
Oncology
Operations Management
Pharmaceutical Industry
Pharmaceutical Sales
Pharmaceutics
Product Development
Product Launch
Product Marketing
Project Management
Sales
Sales Effectiveness
Sales Growth
Sales Operations
Strategic Alliances
Strategic Partnerships
Strategic Planning
Strategy
Top Line Growth
Transformation
Turnarounds
Vendor Relations
Working with Investors
Dave Mullarkey Summary
Dave Mullarkey, based in Menlo Park, CA, US, is currently a Chief Executive Officer at ClearNote Health. Dave Mullarkey brings experience from previous roles at Omniome (Acquired by Pacific Biosciences NASDAQ: PACB for $800M), Roche Molecular Solutions, Ariosa Diagnostics (Acquired by Roche OTCQX: RHHBY for $625M) and Valeant Pharmaceuticals International (now Bausch Health NYSE: BHC). Dave Mullarkey holds a B.S. in Applied Economics & Business Management - Dyson School of Management @ Cornell University. With a robust skill set that includes Biotechnology, Bottom Line Growth, Business Development, Business Planning, Change Management and more. Dave Mullarkey has 2 emails and 1 mobile phone numbers on RocketReach.
Looking for a different Dave Mullarkey?
Find contact details for 700 million professionals.